The European Medicines Agency has published a list
of all new human medicines under evaluation by the Committee for Medicinal
Products for Human Use (CHMP).
The list includes the international non-proprietary names (INNs) and
therapeutic areas for all new innovative medicines under evaluation, along with
information on the type of salt, ester or derivative of the active substance.
For generic and biosimilar medicines, it includes the INN and therapeutic area.
The list only includes medicines whose applications have been validated.
This initiative forms part of the drive towards increased transparency on
its activities by the Agency and other European regulatory authorities. It
follows the publication of recommendations on transparency of ongoing
evaluations adopted by the European Medicines Agency and the Heads of Medicines
Agencies in November 2010.
INNs or generic names are the globally recognised names used to identify
active ingredients in pharmaceuticals. INNs are selected by the World Health Organization
(WHO).